Peninsula Orthopaedic Associates is devoted to providing you with the highest quality of orthopaedic care. POA is dedicated to advancing the field of medicine through thoughtful and groundbreaking clinical research. Results from the clinical research we have completed and will continue to participate in, will greatly impact and improve the quality of life our patients will experience.
Current clinical research studies
- Regentis- Gelrin- C Sage Clinical Study (Dr. Jason Scopp)- Enrollment Paused
- Peninsula Orthopaedic Associates is currently enrolling patients into the SAGE Clinical Study to assess the safety and efficacy of GelrinC for the treatment of articular cartilage damage in the knee.
- If you are 18-50 years old and have pain in only one knee, you may qualify. This is an FDA-regulated clinical study and specific criteria must be followed to determine who is eligible to participate.
- Symptoms of damaged knee cartilage include: activity-related swelling and pain and trouble doing things you enjoy because of the condition of your knee. If this sounds like you, or if you have been told by a doctor that your knee cartilage is damaged, please contact us about participating in our research study.
- Limited space is available and not all types of damaged knee cartilage are suitable for this study.
- For more information, please contact our office 410-749-4154 or visit, https://www.gelrinc.com/sage-clinical-study/
- Cartiheal-Agili-C IDE Clinical Study (Dr. Jason Scopp)- Enrollment Closed
- This clinical study is a prospective, multi-center, open-label, randomized, and controlled trial of Agili-C™ vs. surgical standard of care (SSOC), micro-fracture or debridement, for the treatment of joint surface lesions of the knee.
- For more information and to learn about eligibility requirements, please contact our office 410-749-4154 or visit https://www.cartiheal.com/clinical-study/
- Novocart 3D Aesculap Biologics (Dr. Jason Scopp)– Currently Enrolling
- For more information on the Clinical Study please visit, https://www.aesculapbiologics.com/en/healthcare-professionals/novocart-3d-clinical-trial.html
Completed Clinical Research Studies
- Arthrex Eclipse Total Shoulder Replacement System (Dr. Thomas Brandon)
- Outcomes of a rigorous medical device study begun in 2012 and supported by Dr. Thomas Brandon and the Peninsula Orthopaedic Associates (POA) clinical research team has resulted in FDA approval for patient use of the Arthrex Eclipse Total Shoulder Replacement system effective August 1, 2019. POA was one of sixteen (16) national sites selected to participate in a research study that evaluated the effectiveness of a total shoulder replacement system, through Arthrex, a global leader in orthopedic surgical device designs, research, manufacturing and medical education.
- Dr. Thomas Brandon, a primary investigator in the study stated, “We have participated in this randomized clinical research study since 2012 and each patient in the study was followed for 24 months after surgery. It has been a privilege to be part of this cutting-edge research and these significant advancements in shoulder replacements to provide better outcomes for our patients.” Dr. Brandon also mentioned, “the Eclipse Total Shoulder Replacement System replicates the true anatomy and function of the shoulder. With this advancement, this Eclipse system has several advantages such as: decreased operating time, reduced bone removal, and improved shoulder function, compared to other devices that utilize the traditional stemmed total shoulder arthroplasty.”
- Arthrex commented, “The Eclipse system is a novel, less invasive, bone-preserving total shoulder replacement that has been clinically proven in Europe and Canada with more than 20,000 successful implantations over the past 14 years. The Eclipse system was the first total shoulder implant to replace traditional long stem fixation with short, fenestrated cage screw fixation for bone in growth, eliminating the need for bone cement. Its success as a total shoulder replacement has been demonstrated by outstanding long-term clinical results for the treatment of shoulder arthritis.”